Recently, I reviewed the processes that are used for the production of mRNA vaccines, and I thought it would be appropriate to write also about the production of vector adenovirus vaccines, such as J&J, Oxford / AstraZeneca, CanSino, NICEM Gamaleya and others. It is a completely different system, with its own advantages and disadvantages and with its own long history of scaling up production, where there are trade-offs at every step. It is always difficult to break free from the limitations of the engineering triad: "Fast, Cheap, Quality - choose any two." In other words, if something is done cheaply and with high quality, then hardly quickly, or if quickly and efficiently, then hardly cheap. And, of course, if it is fast and cheap, then it is hardly of any quality!
Supplement: Reviews for further reading on the topic can be found here , here , here , here and here .
Introduction: Adenoviruses and Infections
Adenoviruses are very common double-stranded DNA pathogens and it seems indisputable that anyone reading these lines has contracted several of them during their lifetime. They tend to cause mild respiratory symptoms and sometimes manifest as ear infections or conjunctivitis. We do not have any antiviral drugs or vaccines against adenoviruses in the public domain (although there have been attempts by the military to develop antiviral drugs). Subtypes: There are at least 88 subtypes that are capable of infecting humans (more since this article was published!), Divided into several related groups. Among the most common are adenovirus of the fifth subtype (Ad5), and in some regions the world can be found 80-90% of the population is already seropositive.
, , , . , , , , , , , . Ad-, , J&J . . . Ad26, Oxford / AZ ( ), ReiThera .. , CanSino, Ad5 .
, , , - ? , , , - - . : ( ?) , , , ? - Ad5, Ad26 ?
, , -. - . , , - , , -«» . , ( , ), -. , , , . , - , , . , , ( ).
, , . , , . , E1, . , , E3. - , .
, , , . , - () , , , . ( ) , E1 , , , . , , . E1, , ( ), . , E1.
, - . , . , , , - , ( , ) A5 , E1 E3 , , . - , (bacterial artificial chromosome, BAC), , , . , J&J . . . Ad26, Oxford/AZ , Ad5 - . CanSino AdMax Microbix (Toronto) . , , ( ), . () , , , . BAC , , . / , , . . J&J, .
, , Oxford / AZ BAC, «», E1 . ( , , ). , , J&J ( , , Ad26).
. , . , Oxford/AZ, CanSino HEK293, J&J PER.C6. . HEK « » (human embryonic kidney, HEK), , 1970- . PER.C6 1998 , 1985 , , «ER» « ». , , . , , , - - , .
, " " (virus seed stock) « -» (host cell bank). , , , , - . , , / . , , .
- - , . , , , , . () . , . , . , AstraZeneca , - , , ( , ..)
HEK293, , , , (, HEK293A) , (HKE293S). , ( , ), . , , , , ( "" - ). , - . , ( ), ( ), , , ... , .
, ( , ), , , "", ( --), "", , . ? - , , . , ? ?
, , . ( ) - , , , , , . , . AstraZeneca, , , (, - , ) . , , , , . , , , .
, , . , , . . . . (. ); , . , "/", - .
,
, Oxford/AZ , Advent ( , ) COBRA Biologics ( , ) . Symbiosis ( , ). Catalent (, ), (, ) /. (Halix) (Novasep, Seneffe). , -, . , , IDT Biologika. R-Pharm , ( . . . ). Insud , . AZ , WuXi , . , .
J&J, , (, ), Emergent ( AstraZeneca , Novavax, ). Catalent ( , , , ), Reig Jofre , Aspen Pharmacare ( -, ), Biological E ( -), PCI Pharma . , .
, , . , , ( , , - !). , , , ( ). , - , !